{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:06:57Z","timestamp":1787022417614,"version":"build-2736575974"},"reference-count":45,"publisher":"Japan Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2014]]},"DOI":"10.1507\/endocrj.ej13-0423","type":"journal-article","created":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T20:08:12Z","timestamp":1383336492000},"page":"111-117","source":"Crossref","is-referenced-by-count":105,"title":["Decreased myo-inositol to chiro-inositol (M\/C) ratios and increased M\/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls"],"prefix":"10.1507","volume":"61","author":[{"given":"Douglas","family":"Heimark","sequence":"first","affiliation":[{"name":"Department of Pharmacology, University of Virginia, Charlottesville, VA 22903 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"McAllister","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Pennsylvania State University College of Medicine, Hershey, PA, 17033 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Larner","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Virginia, Charlottesville, VA 22903 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Franks S, Gharani N, Waterworth D, Batty S, White D, et al. (1997) The genetic basis of polycystic ovary syndrome. Hum Reprod<\/i> 12: 2641-2648.","DOI":"10.1093\/humrep\/12.12.2641"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Goldzieher J (1981) Polycystic ovarian disease. Fertil Steril<\/i> 35: 371-394.","DOI":"10.1016\/S0015-0282(16)45429-4"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Barnes R, Rosenfield RL (1989) The polycystic ovary syndrome: pathogenesis and treatment. Ann Intern Med<\/i> 110: 386-399.","DOI":"10.7326\/0003-4819-110-5-386"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Barnes RB, Rosenfield RL, Burstein S, Ehrmann DA (1989) Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med<\/i> 320: 559-565.","DOI":"10.1056\/NEJM198903023200904"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Goldzeiher JW, Green JA (1962) The polycystic ovary. I. Clinical and histologic features. J Clin Endocrinol Metab<\/i> 22: 325-338.","DOI":"10.1210\/jcem-22-3-325"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Erickson GF, Magoffin DA, Dyer CA, Hofeditz C (1985) The ovarian androgen producing cells: a review of structure\/function relationships. Endocr Rev<\/i> 6: 371-399.","DOI":"10.1210\/edrv-6-3-371"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Larner J, Craig J (1996) Urinary myo-inositol-to-chiro-inositol ratios and insulin resistance. Diabetes Care<\/i> 19: 76-78.","DOI":"10.2337\/diacare.19.1.76"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kennington A, Hill C, Craig J, Bogardus C, Raz I, et al. (1990) Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. N Engl J Med<\/i> 323: 373-378.","DOI":"10.1056\/NEJM199008093230603"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Asplin I, Galasko G, Larner J (1993) chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci U S A<\/i> 90: 5924-5928.","DOI":"10.1073\/pnas.90.13.5924"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Suzuki S, Kawasaki H, Satoh Y, Ohtomo M, Hirai M, et al. (1994) Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type II diabetes. Diabetes Care<\/i> 17: 1465-1468.","DOI":"10.2337\/diacare.17.12.1465"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Shashkin P, Shashkina E, Fernqvist-Forbes E, Zhou Y, Grill V, et al. (1997) Insulin mediators in man: effects of glucose ingestion and insulin resistance. Diabetologia<\/i> 40: 557-563.","DOI":"10.1007\/s001250050715"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Baillargeon J-P, Iuorno MJ, Apridonidze T, Nestler JE (2010) Uncoupling Between Insulin and Release of a D-Chiro-Inositol—Containing Inositolphosphoglycan Mediator of Insulin Action in Obese Women With Polycystic Ovary Syndrome. Metab Syndr Relat Disord<\/i> 8: 127-136.","DOI":"10.1089\/met.2009.0052"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Scioscia M, Gumaa K, Kunjara S, Paine M, Selvaggi L, et al. (2006) Insulin resistance in human preeclamptic placenta is mediated by serine phosphorylation of insulin receptor substrate-1 and -2. J Clin Endocrinol Metab<\/i> 91: 709-717.","DOI":"10.1210\/jc.2005-1965"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Larner J, Price J, Heimark D, Smith L, Rule G, et al. (2003) Isolation, structure, synthesis, and bioactivity of a novel putative insulin mediator. A galactosamine chiro-inositol pseudo-disaccharide Mn2+ chelate with insulin-like activity. J Med Chem<\/i> 46: 3283-3291.","DOI":"10.1021\/jm030071j"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Pak Y, Hong Y, Kim S, Piccariello T, Farese RV, et al. (1998) In vivo<\/i> chiro-Inositol metabolism in the rat: A defect in chiro-Inositol synthesis from myo-Inositol and an increased incorporation of chiro-[3<\/sup>H]Inositol into phospholipid in the Goto-Kakizaki (G.K.) rat. Mol Cells<\/i> 8: 301-309.","DOI":"10.1016\/S1016-8478(23)13428-5"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Sun T, Heimark D, Nguygen T, Nadler J, Larner J (2002) Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun<\/i> 293: 1092-1098.","DOI":"10.1016\/S0006-291X(02)00313-3"},{"key":"17","unstructured":"17. McAllister J, Simpson E. Human theca interna cells in culture. Methods in Toxicology. 3. San Diego: Academic Press; 1993. p. 330-339."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Nelson VL, Legro RS, Strauss JF, McAllister JM (1999) Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol<\/i> 13: 946-957.","DOI":"10.1210\/mend.13.6.0311"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Nelson-DeGrave VL, Wickenheisser JK, Cockrell JE, Wood JR, Legro RS, et al. (2004) Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology<\/i> 145: 799-808.","DOI":"10.1210\/en.2003-0940"},{"key":"20","unstructured":"20. Wickenheisser JK, Quinn PG, Nelson VL, Legro RS, Strauss JF, et al. (2000) Differential activity of the cytochrome P450 17α-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells. J Clin Endocrinol Metab<\/i> 85: 2304-2311."},{"key":"21","unstructured":"21. Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens J, Hazeltine F, Merriam G, editors. Polycystic ovary syndrome Current issues in endocrinology and metabolism Boston: Blackwell. Boston: Blackwell Scientific; 1992. p. 377-384."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Legro RS, Driscoll D, Strauss III JF, Fox J, Dunaif A (1998) Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A<\/i> 95: 14956-14960.","DOI":"10.1073\/pnas.95.25.14956"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Wickenheisser JK, Biegler JM, Nelson-DeGrave VL, Legro RS, Strauss JF, et al. (2012) Cholesterol Side-Chain Cleavage Gene Expression in Theca Cells: Augmented Transcriptional Regulation and mRNA Stability in Polycystic Ovary Syndrome. PLoS One<\/i> 7: e48963.","DOI":"10.1371\/journal.pone.0048963"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Gilling-Smith C, Story H, Rogers V, Franks S (1997) Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxf)<\/i> 47: 93-99.","DOI":"10.1046\/j.1365-2265.1997.2321049.x"},{"key":"25","unstructured":"25. Jakubowicz D, Nestler J (1997) 17α-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss. J Clin Endocrinol Metab<\/i> 82: 556-560."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Nestler J (1998) Inositolphosphoglycans (IPGs) as mediators of insulin\u2019s steroidogenic actions. J Basic Clin Physiol Pharmacol<\/i> 9: 197-204.","DOI":"10.1515\/JBCPP.1998.9.2-4.197"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Nelson VL, Qin K, Rosenfield RL, Wood JR, Penning TM, et al. (2001) The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab<\/i> 86: 5925-5933.","DOI":"10.1210\/jcem.86.12.8088"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Daneshmand S, Weitsman SR, Navab A, Jakimiuk AJ, Magoffin DA (2002) Overexpression of theca-cell messenger RNA in polycystic ovary syndrome does not correlate with polymorphisms in the cholesterol side-chain cleavage and 17α-hydroxylase\/C17-20 lyase promoters. Fertil Steril<\/i> 77: 274-280.","DOI":"10.1016\/S0015-0282(01)02999-5"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Wickenheisser JK, Nelson-DeGrave VL, McAllister JM (2005) Dysregulation of cytochrome P450 17α-hydroxylase messenger ribonucleic acid stability in theca cells isolated from women with polycystic ovary syndrome. J Clin Endocrinol Metab<\/i> 90: 1720-1727.","DOI":"10.1210\/jc.2004-1860"},{"key":"30","unstructured":"30. Nestler JE, Jakubowicz DJ, Falcon de Vargas A, Brik C, Quintero N, et al. (1998) Insulin Stimulates Testosterone Biosynthesis by Human Thecal Cells from Women with Polycystic Ovary Syndrome by Activating Its Own Receptor and Using Inositolglycan Mediators as the Signal Transduction System. J Clin Endocrinol Metab<\/i> 83: 2001-2005."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Alvarez JF, Varela I, Ruiz-Albusac JM, Mato JM (1988) Localisation of the insulin-sensitive phosphatidylinositol glycan at the outer surface of the cell membrane. Biochem Biophys Res Commun<\/i> 152: 1455-1462.","DOI":"10.1016\/S0006-291X(88)80449-2"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Alvarez J, Sánchez-Arias J, Guadaño A, Estévez F, Varela I, et al. (1991) Transport in isolated rat hepatocytes of the phospho-oligosaccharide that mimics insulin action. Effects of adrenalectomy and glucocorticoid treatment. Biochem J<\/i> 274 369-374.","DOI":"10.1042\/bj2740369"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Hans SK, Camara F, Altiti A, Martín-Montalvo A, Brautigan DL, et al. (2010) Synthesis of C-glycoside analogues of β-galactosamine-(1-->4)-3-O-methyl-D-chiro-inositol and assay as activator of protein phosphatases PDHP and PP2Cα. Bioorg Med Chem<\/i> 18: 1103-1110.","DOI":"10.1016\/j.bmc.2009.12.056"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Livingstone C, Collison M (2002) Sex steroids and insulin resistance. Clin Sci<\/i> 102: 151-166.","DOI":"10.1042\/cs1020151"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Bhasin S (2003) Effects of Testosterone Administration on Fat Distribution, Insulin Sensitivity, and Atherosclerosis Progression. Clin Infect Dis<\/i> 37: S142-S149.","DOI":"10.1086\/375878"},{"key":"36","unstructured":"36. Mårin P, Holmäng S, Jönsson L, Sjöström L, Kvist H, et al. (1992) The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord<\/i> 16: 991-997."},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Diamanti-Kandarakis E, Dunaif A (2012) Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications. Endocr Rev<\/i> 33: 981-1030.","DOI":"10.1210\/er.2011-1034"},{"key":"38","unstructured":"38. Book C-B, Dunaif A (1999) Selective Insulin Resistance in the Polycystic Ovary Syndrome. J Clin Endocrinol Metab<\/i> 84: 3110-3116."},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Eriksen M, Pørneki AD, Skov V, Burns JS, Beck-Nielsen H, et al. (2010) Insulin Resistance Is Not Conserved in Myotubes Established from Women with PCOS. PLoS One<\/i> 5: e14469.","DOI":"10.1371\/journal.pone.0014469"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Carlomagno G, Unfer V, Roseff S (2011) The D-chiro-inositol paradox in the ovary. Fertil Steril<\/i> 95: 2515-2516.","DOI":"10.1016\/j.fertnstert.2011.05.027"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Farese RV, Rosic N, Babischkin J, Farese MG, Foster R, et al. (1986) Dual activation of the inositol-triphosphate-calcium and cyclic nucleotide intracellular signaling systems by adrenocorticotropin in rat adrenal cells. Biochem Biophys Res Commun<\/i> 135: 742-748.","DOI":"10.1016\/0006-291X(86)90991-5"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. York SJ, Armbruster BN, Greenwell P, Petes TD, York JD (2005) Inositol Diphosphate Signaling Regulates Telomere Length. J Biol Chem<\/i> 280: 4264-4269.","DOI":"10.1074\/jbc.M412070200"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Chakraborty A, Koldobskiy MA, Bello NT, Maxwell M, Potter JJ, et al. (2010) Inositol Pyrophosphates Inhibit Akt Signaling, Thereby Regulating Insulin Sensitivity and Weight Gain. Cell<\/i> 143: 897-910.","DOI":"10.1016\/j.cell.2010.11.032"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Brautigan D, Brown M, Grindrod S, Chinigo G, Kruszewski A, et al. (2005) Allosteric activation of protein phosphatase 2C by D-chiro-inositol-galactosamine, a putative mediator mimetic of insulin action. Biochemistry<\/i> 44: 11067-11073.","DOI":"10.1021\/bi0508845"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Lin X, Ma L, Gopalan C, Ostlund RE (2009) D- chiro-Inositol is absorbed but not synthesised in rodents. Br J Nutr<\/i> 102: 1426-1434.","DOI":"10.1017\/S0007114509990456"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/61\/2\/61_EJ13-0423\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T01:51:40Z","timestamp":1716083500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/61\/2\/61_EJ13-0423\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej13-0423","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718398264.793495480","asserted-by":"object"}]},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}